Combination lipid-lowering therapy, rather than high-intensity statin monotherapy, is proposed as a first-line standard of care to achieve LDL cholesterol goals in very high-risk patients.
Combination lipid-lowering therapy as first line strategy in very high-risk patients. Combination lipid-lowering therapy as first line strategy in very high-risk patients.
Ray et al. (Thu,) conducted a editorial in Very high-risk atherosclerotic cardiovascular disease. Combination lipid-lowering therapy vs. Statin monotherapy was evaluated. Combination lipid-lowering therapy, rather than high-intensity statin monotherapy, is proposed as a first-line standard of care to achieve LDL cholesterol goals in very high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: